Efficacy of Vandetanib in Treating Locally Advanced or Metastatic Medullary Thyroid Carcinoma According to RECIST Criteria: A Systematic Review and Meta-Analysis

Efficacy of Vandetanib in Treating Locally Advanced or Metastatic Medullary Thyroid Carcinoma According to RECIST Criteria: A Systematic Review and Meta-Analysis

BackgroundVandetanib is the most largely used tyrosine kinase inhibitor (TKI) in patients with locally advanced and/or metastatic medullary thyroid cancer (MTC). Here, we conducted a systematic review on its efficacy and attempted to perform a meta-analysis adopting standardized RECIST criteria as e...

Full description

Bibliographic Details
Main Authors: Pierpaolo Trimboli, Marco Castellana, Camilla Virili, Francesco Giorgino, Luca Giovanella
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-05-01
Series:Frontiers in Endocrinology
Subjects:
medullary thyroid carcinoma
tyrosine kinase inhibitors
vandetanib
RECIST
systematic review
meta-analysis
Online Access:http://journal.frontiersin.org/article/10.3389/fendo.2018.00224/full

Internet

http://journal.frontiersin.org/article/10.3389/fendo.2018.00224/full

Similar Items